Infrequent p53 gene alterations in ulcerative colitis

Brazilian Journal of Medical and Biological Research

Volumn 32, Issue 9, 1999, Pages 1083-1088

  Mattar, R ^a   Alexandrino, A M ^a   Laudanna, A A ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

LOH; Mutation; p53 gene; Ulcerative colitis

Indexed keywords

BIOLOGICAL MARKER;

ADULT; ARTICLE; FEMALE; GENETICS; HUMAN; MALE; MIDDLE AGED; MUTATION; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; RISK FACTOR; TUMOR SUPPRESSOR GENE; ULCERATIVE COLITIS;

ADULT; BIOLOGICAL MARKERS; COLITIS, ULCERATIVE; FEMALE; GENES, P53; HUMANS; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; RISK FACTORS;

EID: 0033195066     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X1999000900005     Document Type: Article

References (36)

1. Lane DP & Crawford LV (1979). T antigen is bound to a host protein in SV 40-transformed cells. Nature, 278: 261-263.
2. Linzer DIH, Maltzman W & Levine AJ (1979). The SV 40 A gene product is required for the production of a 54,000 MW cellular tumor antigen. Virology, 998: 308-318.
3. Finlay CA, Hinds PW, Tan T-H, Eliyahu D, Oren M & Levine AJ (1988). Activating mutations for transformation by p53 produce a gene product that forms a hsc-70-p53 complex with an altered half-life. Molecular and Cellular Biology, 8: 531-539.
4. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC & Vogelstein B (1989). Mutations in the p53 gene occur in diverse human tumour types. Nature, 342: 705-708.
5. Hinds PW, Finlay CA, Quartin RS, Baker SJ, Fearon ER, Vogelstein B & Levine AJ (1990). Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes. Cell Growth and Differentiation, 1 : 571-580.
6. Baker SJ, Preisinger AC, Jessup JM, Paraskeva C, Markowitz S, Willson JKV, Hamilton S & Vogelstein B (1990). p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Research, 50: 7717-7722.
7. Parada LF, Land H, Weinberg RA, Wolf D & Rotter V (1984). Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation. Nature, 312: 649-651.
8. Eliyahu D, Raz A, Gruss P, Givol D & Oren M (1984). Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature, 312: 646-649.
9. Levine AJ, Momand J & Finlay CA (1991). The p53 tumour suppressor gene. Nature, 351: 453-456.
10. Rodrigues NR, Rowan A, Smith MEF, Kerr IB, Bodmer WF, Gannon JV & Lane DP (1990). p53 mutations in colorectal cancer. Proceedings of the National Academy of Sciences, USA, 87: 7555-7559.
11. Greenwald BD, Harpaz N, Yin J, Huang Y, Tong Y, Brown VL, McDaniel T, Newkirk C, Resau JH & Meltzer SJ (1992). Loss of heterozygosity affecting the p53, Rb, and mcc/apc tumor suppressor gene loci in dysplastic and cancerous ulcerative colitis. Cancer Research, 52: 741-745.
12. Yin J, Harpaz N, Tong Y, Huang Y, Laurin J, Greenwald BD, Hontanosas M, Newkirk C & Meltzer SJ (1993). p53 point mutations in dysplastic and cancerous ulcerative colitis lesions. Gastroenterology, 104: 1633-1639.
13. Chaubert P, Benhattar J, Saraga E & Costa J (1994). K-ras mutations and p53 alterations in neoplastic and nonneoplastic lesions associated with longstanding ulcerative colitis. American Journal of Pathology, 144: 767-775.
14. Brentnall TA, Crispin DA, Rabinovitch PS, Haggitt RC, Rubin CE, Stevens AC & Burmer GC (1994). Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology, 107: 369-378.
15. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B & Craig RW (1991). Participation of p53 protein in the cellular response to DNA damage. Cancer Research, 51: 6304-6311.
16. Chen J, Jackson PK, Kirschner MW & Dutta A (1995). Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature, 374: 386-388.
17. Waga S, Hannon GJ, Beach D & Stillman B (1994). The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature, 369: 574-578.
18. Shaw P, Bovey R, Tardy S, Sahli R, Sordat B & Costa J (1992). Induction of apoptosis by wild-type p53 in a human colon tumorderived cell line. Proceedings of the National Academy of Sciences, USA, 89: 4495-4499.
19. 1 arrest and apoptosis. Cancer Research, 54: 1169-1174.
20. Knudson Jr AG (1985). Hereditary cancer oncogenes and antioncogenes. Cancer Research, 45: 1437-1443.
21. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AMM & Bos JL (1988). Genetic alterations during colorectal-tumor development. New England Journal of Medicine, 319: 525-532.
22. Yokota J & Sugimura T (1993). Multiple steps in carcinogenesis involving alterations of multiple tumor suppressor genes. FASEB Journal, 7: 920-925.
23. Riddell RH, Goldman H, Ransohoff DF, Appelman HD, Fenoglio CM, Haggitt RC, Ahren C, Correa P, Hamilton SR, Morson BC, Sommers SC & Yardley JH (1993). Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Human Pathology, 14: 931-968.
24. Sambrook J, Fritsch EF & Maniatis T (1989). Molecular Cloning - A Laboratory Manual. 2nd edn. Cold Spring Harbor Laboratory, New York.
25. McDaniel T, Carbone D, Takahashi T, Chumakov P, Chang EH, Pirollo KF, Yin J, Huang Y & Meltzer SJ (1991). The Mspl polymorphism in intron 6 of p53 (TP53) detected by digestion of PCR products. Nucleic Acids Research, 19: 4796.
26. De la Calle-Martin O, Fabregat V, Romero M, Soler J, Vives J & Yägue J (1990). AccII polymorphism of the p53 gene. Nucleic Acids Research, 18: 4963.
27. Tohdo H, Yokozaki H, Haruma K, Kajiyama G & Tahara E (1993). p53 gene mutations in gastric adenomas. Virchows Archiv. B, Cell Pathology, 63: 191-195.
28. Lashner BA, Silverstein MD & Hanauer SB (1989). Hazard rates for dysplasia and cancer in ulcerative colitis. Digestive Diseases and Sciences, 34: 1536-1541.
29. Gyde SN, Prior P, Allan RN, Stevens A, Jewell DP, Truelove SC, Lofberg R, Brostrom O & Hellers G (1998). Colorectal cancer in ulcerative colitis: a cohort study of primary referrals from three centres. Gut, 29: 206-217.
30. Papatheodoridis GV, Zizi A-S, Xourgias V, Elemenoglou I & Karamanolis DG (1998). Indefinite dysplasia in ulcerative colitis has little clinical significance and is not associated with p53 protein accumulation. American Journal of Gastroenterology, 93: 285-286.
31. Fogt F, Vortmeyer AO, Goldman H, Giordano TJ, Merino MJ & Zhuang Z (1998). Comparison of genetic alterations in colonic adenoma and ulcerative colitis-associated dysplasia and carcinoma. Human Pathology, 29: 131-136.
32. Ozturk M, Bressac B, Puisieux A, Kew M, Volkmann M, Bozcall S, Mura JB, De la Mont S, Carlson R, Blum H, Wands J, Takahashi H, Von Weizsäcker F, Galun E, Kar S, Car BI, Schröder CH, Erken E, Varinli S, Rustgi VK, Prat J, Toda G, Koch HK, Liang XH, Tang Z-Y, Shouval D, Lee H-S, Vyas GN & Sarosi I (1991). p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet, 338: 1356-1359.
33. Cartwright CA, Coad CA & Egbert BM (1994). Elevated c-src tyrosine kinase activity in premalignant epithelia of ulcerative colitis. Journal of Clinical Investigations, 93: 509-515.
34. Itzkowitz SH, Marshall A, Kornbluth A, Harpaz N, McHugh JBD, Ahnen D & Sachar DB (1995). Sialosyl-Tn antigen: initial report of a new marker of malignant progression in long-standing ulcerative colitis. Gastroenterology, 109: 490-497.
35. Suzuki H, Harpaz N, Tarmin L, Yin J, Jiang H-Y, Bell JD, Hontanosas M, Groisman GM, Abraham JM & Meltzer SJ (1994). Microsatellite instability in ulcerative colitis-associated colorectal dysplasias and cancers. Cancer Research, 54: 4841-4846.
36. Bretnall TA, Crispin DA, Bronner MP, Cherian SP, Hueffed M, Rabinovitch PS, Rubin CE, Haggitt RC & Boland CR (1996). Microsatellite instability in nonneoplastic mucosa from patients with chronic ulcerative colitis. Cancer Research, 56: 1237-1240.